Synonyms: HM781-36B | NOV120101
Compound class:
Synthetic organic
Comment: Poziotinib is an orally bioavailable, clinically active, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with antineoplastic activity [1-2]. It is a potent inhibitor of the most common EGFR and HER2 exon 20 insertion mutants that are predominantly activating in nature, and resistant to exisitng reversible and irreversible EGFR tyrosine kinase inhibitors [3-4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Poziotinib has advanced to Phase 2 clinical trial either alone or in combination for several types of advanced solid malignancies. Click here to link to ClinicalTrials.gov's full list of poziotinib trials. [4] |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03066206 | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Phase 2 Interventional | M.D. Anderson Cancer Center | Preliminary results from a small cohort of 11 patients with NSCLC and EGFR exon 20 insertion mutations, indicated a response rate of 64%. This appears impressive, but it's important to note this trial is not yet complete, and median PFS and OS have yet to be reported. | 3 |